Close
March 2018
(This course is run by Cell and Gene Therapy Catapult and supported by UCL. This course is not UCL accredited).
The course objective is to challenge delegates to think about the commercial product, market, and process from the outset and to use that information to inform the process development and manufacturing strategy for clinical trials and routine manufacture. This will be achieved through lectures from a wide range of experienced, successful, international industrialists building on a solid framework of regulatory requirements. The experience gained will be put to use in developing case study processes and understanding how these processes relate to cost of goods models and what factors most impact the cost of goods.
For bookings please visit the Eventbrite page
Previous Expert Speakers Include
Stephen Ward, Cell and Gene Therapy Catapult (Module Leader)
Chris Mason, UCL (Module Leader)
Angela Osborne, eXmoor pharma
Lucy Foley, Centre for Process Innovation
Sharon Grimster, ReNeuron
Bruce Levine, University of Pennsylvania
Michael Roberts, Synpromics
Panos Kefalas, Cell and Gene Therapy Catapult
Dan Williams, Adaptimmune
Paddy Ginty, GSK
Michael Linden, Pfizer
Jan Thirkettle, Freeline Therapeutics
Suzanne Farid, UCL
Dave Wilson, Thermo Fisher
James Miskin, Oxford BioMedica
Thomas Fellner, Lonza Biologics
Kim Warren, CCRM
Dave Smith, Lonza Biologics
Farzin Farzaneh, King’s College
Otto Merten, Genethon
Anthony Davies, Dark Horse Consulting
Geoff MacKay, AVROBIO
A networking dinner will be held on the first evening.
For further information and please contact:
E: mbi-training@ucl.ac.uk
T: +44 (0) 20 7679 9619 l +44 (0) 203 549 5619